Literature DB >> 24633870

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Denise Wolleschak1, Thomas S Mack1, Florian Perner1, Stephanie Frey1, Tina M Schnöder1, Marie-Christine Wagner1, Christine Höding1, Marina C Pils2, Andreas Parkner3, Stefanie Kliche4, Burkhart Schraven5, Katrin Hebel6, Monika Brunner-Weinzierl6, Satish Ranjan7, Berend Isermann7, Daniel B Lipka8, Thomas Fischer1, Florian H Heidel9.   

Abstract

Entities:  

Keywords:  AC220; FLT3-ITD; PKC412; T-cell activation; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2014        PMID： 24633870      PMCID： PMC4040902          DOI： 10.3324/haematol.2014.104331

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

Authors:  Claudine Graf; Florian Heidel; Stefan Tenzer; Markus P Radsak; Fian K Solem; Cedrik M Britten; Christoph Huber; Thomas Fischer; Thomas Wölfel
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Authors:  Florian Heidel; Fian K Solem; Frank Breitenbuecher; Daniel B Lipka; Stefan Kasper; M H Thiede; Christian Brandts; Hubert Serve; Johannes Roesel; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary J Schiller; Stephen Nimer; Richard M Stone; Yanfeng Wang; Thomas Kindler; Pamela S Cohen; Christoph Huber; Thomas Fischer
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.

Authors:  Matthias Wölfl; Stefanie Schwinn; Young-Eun Yoo; Marie L Reß; Matthias Braun; Martin Chopra; Susanne C Schreiber; Victor I Ayala; Claes Ohlen; Matthias Eyrich; Andreas Beilhack; Paul G Schlegel
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

Review 4.  Antigen-specific cellular immunotherapy of leukemia.

Authors:  A Van Driessche; L Gao; H J Stauss; P Ponsaerts; D R Van Bockstaele; Z N Berneman; V F I Van Tendeloo
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

5.  Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.

Authors:  Ruth Seggewiss; Karin Loré; Elisabeth Greiner; Magnus K Magnusson; David A Price; Daniel C Douek; Cynthia E Dunbar; Adrian Wiestner
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

6.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

Review 7.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Authors:  Ellen Weisberg; Paul W Manley; Sandra W Cowan-Jacob; Andreas Hochhaus; James D Griffin
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

8.  Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.

Authors:  Fei Fei; Yingzhe Yu; Anita Schmitt; Markus Thomas Rojewski; Baoan Chen; Jochen Greiner; Marlies Götz; Philippe Guillaume; Hartmut Döhner; Donald Bunjes; Michael Schmitt
Journal:  Exp Hematol       Date:  2008-07-10       Impact factor: 3.084

9.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

10.  Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.

Authors:  J Chen; A Schmitt; B Chen; M Rojewski; V Rübeler; F Fei; Y Yu; X Yu; M Ringhoffer; S von Harsdorf; J Greiner; M Götzz; P Guillaume; H Döhner; D Bunjes; M Schmitt
Journal:  J Cell Mol Med       Date:  2008-01-11       Impact factor: 5.310
View more
  6 in total

1.  Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors:  F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal:  Leukemia       Date:  2015-08-05       Impact factor: 11.528

Review 2.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

3.  Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.

Authors:  Satish Ranjan; Alexander Goihl; Shrey Kohli; Ihsan Gadi; Mandy Pierau; Khurrum Shahzad; Dheerendra Gupta; Fabian Bock; Hongjie Wang; Haroon Shaikh; Thilo Kähne; Dirk Reinhold; Ute Bank; Ana C Zenclussen; Jana Niemz; Tina M Schnöder; Monika Brunner-Weinzierl; Thomas Fischer; Thomas Kalinski; Burkhart Schraven; Thomas Luft; Jochen Huehn; Michael Naumann; Florian H Heidel; Berend Isermann
Journal:  Nat Commun       Date:  2017-08-21       Impact factor: 14.919

4.  Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Authors:  Rim Trad; Walid Warda; Vincent Alcazer; Mathieu Neto da Rocha; Ana Berceanu; Clémentine Nicod; Rafik Haderbache; Xavier Roussel; Yohan Desbrosses; Etienne Daguindau; Florain Renosi; Christophe Roumier; Lucie Bouquet; Sabeha Biichle; Melanie Guiot; Evan Seffar; Denis Caillot; Stephane Depil; Eric Robinet; Yahya Salma; Eric Deconinck; Marina Deschamps; Christophe Ferrand
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

5.  Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.

Authors:  Jaideep B Bharate; Nicholas McConnell; Gunaganti Naresh; Lingtian Zhang; Naga Rajiv Lakkaniga; Lucky Ding; Neil P Shah; Brendan Frett; Hong-Yu Li
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

6.  Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

Authors:  K Reiter; H Polzer; C Krupka; A Maiser; B Vick; M Rothenberg-Thurley; K H Metzeler; D Dörfel; H R Salih; G Jung; E Nößner; I Jeremias; W Hiddemann; H Leonhardt; K Spiekermann; M Subklewe; P A Greif
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.